Phaseline

Companies › SyneuRx International (Taiwan)

SyneuRx International (Taiwan): clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Psychiatry; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
NaBen®
NMDA receptor modulator (GRIN2B antagonist)
GRIN2BPhase 2Refractory SchizophreniaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03094429NaBen®Phase 2Refractory SchizophreniaPsychiatryDec 2026

Targets

GRIN2B (1)

Companies with the same targets

Praxis Precision Medicines Syndeio Biosciences GRIN Therapeutics SHINKEI Therapeutics Aptinyx Neuren Pharmaceuticals BnH Research Johnson & Johnson (Janssen)

Companies built like this

atai Therapeutics Arialys Australia Syndeio Biosciences Draig Therapeutics Kadence Bio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.